A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pembrolizumab (KEYTRUDA)

Pembrolizumab helps the immune system fight cancer by blocking PD-1 immune checkpoints.

First FDA approval2015-01-15
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$228.4M in CY2024 Part D spend19K claims · 4K beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Pembrolizumab used for?

Pembrolizumab helps the immune system fight cancer by blocking PD-1 immune checkpoints.

Is there a generic for Pembrolizumab?

No. Pembrolizumab is brand-only with no generic equivalents currently in market.

How much does my plan pay for Pembrolizumab?

NADAC pricing data not currently available for this drug.

Is Pembrolizumab on the FDA shortage list?

No. Pembrolizumab is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Programmed Death Receptor-1 Blocking Antibody6 alternatives in D1
01
Atezolizumab
Brand: TECENTRIQ
Lowest NADAC
0Generic mfrs
$37.8MCY24 Part D spend
Compare →
02
Atezolizumab and Hyaluronidase-Tqjs
Brand: Tecentriq Hybreza
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Dostarlimab
Brand: Jemperli
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Nivolumab
Brand: OPDIVO
Lowest NADAC
0Generic mfrs
$80.7MCY24 Part D spend
Compare →
05
Nivolumab and Hyaluronidase-Nvhy
Brand: OPDIVO QVANTIG
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Nivolumab and Relatlimab-Rmbw
Brand: OPDUALAG
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.